
Desire, Not Mechanics
Sildenafil and tadalafil work further downstream on blood flow. PT-141 acts on the desire that precedes it.
A prescription drug that works on desire itself, prescribed off-label for men.
PT-141, or bremelanotide, acts on melanocortin receptors in the brain, on the pathways that govern arousal. Sildenafil and tadalafil, the drugs in Viagra and Cialis, work further downstream on blood flow. PT-141 acts on the desire that precedes it.
Its commercial version, Vyleesi, was FDA-approved in 2019 for hypoactive sexual desire disorder in premenopausal women. Prologue's PT-141 is compounded and prescribed off-label. Compounded medications are not FDA-approved.

Sildenafil and tadalafil work further downstream on blood flow. PT-141 acts on the desire that precedes it.

Subcutaneous injection, taken as needed.

Compounded. Active ingredient FDA-approved as Vyleesi for women; prescribed off-label for men.
A consultation with a Prologue physician.
Your blood pressure and your cardiac history, before prescribing.
Compounded. Active ingredient FDA-approved as Vyleesi for women; prescribed off-label for men.
Subcutaneous injection, taken as needed, compounded by a licensed pharmacy partner.
The mechanism is well understood.
The trials behind Vyleesi enrolled premenopausal women with a specific diagnosis and showed a modest effect on desire. No comparable trial has been run in men.
Vyleesi’s trials
The human data is mostly in women.
PT-141 raises blood pressure transiently after each dose. Vyleesi carries a contraindication for uncontrolled hypertension and for known cardiovascular disease, and that contraindication applies here. Your physician checks both before prescribing.


Subcutaneous injection, taken as needed.
There's no established dose for the off-label use. Your physician sets it and adjusts based on how you respond.
Compounded by a licensed pharmacy partner and tested for potency, sterility, and endotoxin levels before shipment.
Bremelanotide (PT-141) is FDA-approved in its commercial form, Vyleesi, for hypoactive sexual desire disorder in premenopausal women. Prologue prescribes it off-label for men. It is compounded by a licensed pharmacy partner and tested for potency, sterility, and endotoxin levels before shipment. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Treatment is not appropriate for every patient, and outcomes vary. Talk with your physician about whether this fits your situation.
PT-141 requires a consultation with a Prologue physician.
Everyone else starts by joining the practice.
Members can bring it up at their next consultation.
Not listed here? Read the full FAQ.